This Phase II trial, sponsored by the University of Virginia, investigates the combination of docetaxel and thalidomide as a second-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Given the high unmet need in NSCLC, particularly in later stages, successful outcomes could position this combination as a viable treatment option, potentially increasing market share in a competitive landscape dominated by established therapies. The trial's completion in 2007 suggests that data may be available for further analysis, which could inform future development strategies or partnerships. The involvement of the National Cancer Institute (NCI) may enhance credibility and facilitate potential funding opportunities or collaborations.